Comparison of the Bioavailability of Fenofibric Acid and Rosuvastatin From ABT-143 Relative to That From the Coadministration of ABT-335 (Fenofibric Acid) and Rosuvastatin Calcium

AstraZeneca90 enrolled

Overview

The purpose of this study is to evaluate the safety and compare the pharmacokinetic parameters from the fixed dose combination ABT-143 relative to that from the co-administration of the two monotherapies.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Healthy

Interventions

ABT-143DRUG

once, see arm description for more information

ABT-335DRUG

once, see arm description for more information

rosuvastatinDRUG

once, see arm description for more detail

Eligibility

Sex: ALLMin age: 18 YearsMax age: 55 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: 1. A condition of general good health 2. BMI 19 to 29 Exclusion Criteria: 1. Currently enrolled in another clinical study 2. Females who are pregnant or breast-feeding

Locations (1)

Site Reference ID/Investigator# 14762

Orlando, Florida, United States

Outcomes

Primary Outcomes

To determine the safety and tolerability of ABT-143 vs (ABT-335 + rosuvastatin) in healthy adults

Time frame: 7 days

To determine the pharmacokinetic profile(s) for ABt-143 vs. (ABT-335 + rosuvastatin) in healthy adults

Time frame: 7 days

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.